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Abstract
Background: The use of oral anticoagulant therapy (OAT) to prevent non-valvular atrial
fibrillation (NVAF) related-strokes is often sub-optimal. We aimed to evaluate whether
implementing guidelines on antithrombotic therapy (AT) by a multifaceted strategy may improve
appropriateness of its prescription in NVAF-patients discharged from a large tertiary-care hospital.
Methods: A survey was conducted on all consecutive NVAF patients discharged before (1st
January–30th June 2000, n = 313) and after (1st January–30th June 2004, n = 388) guideline
development and implementation.
Results: When strongly recommended, OAT use increased from 56.6% (60/106 in 2000) to 81.9%
(86/105 in 2004), with an absolute difference of +25.3% (95%CI: 15% 35%). In patients for whom
the choice OAT/acetylsalicylic acid should be individualised, those discharged without any AT were
33.7% (34/101) in 2000 and 16.9% (21/124) in 2004 (-16.7%;95%CI: -26.2% -7.2%). In a logistic
regression model, OAT prescription in 2004 was increased by 2.11 times (95%CI: 1.47 3.04), after
accounting for stroke risk, presence of contraindications (OR = 0.18; 0.13 0.27), older age (OR =
0.30; 0.21 0.45), prophylaxis at admission (OR = 3.03; 2.08 4.43). OAT was positively associated
with the stroke risk in the 2004 sample only.
Conclusion: The guideline implementation has substantially improved the appropriateness of
OAT at discharge, through a better evaluation at patient's individual level of the benefit-to-risk
ratio.
Background
Non-valvular atrial fibrillation (NVAF) is associated with
a six-fold increased stroke risk, accounting roughly for 20–
25% of ischaemic stroke in older patients [1]. With the
increasing population ageing, the burden of NVAF is
expected to double in the near future, with important
public health implications [2]. It has been shown that oral
anticoagulation therapy (OAT) and acetylsalicylic acid
(ASA) can respectively reduce the risk of stroke by 50–
60% and 10–15% in patients at higher thromboembolic
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much less evident for lower risk patients (stroke rate ≤2%/
year) [3]. Further, the effectiveness of OAT is well demon-
strated in clinical practice, without an exceeding risk of
bleeding complications, even in older patients [4,5]. Nev-
ertheless, recent surveys have shown that warfarin is still
largely underused, being the proportion of treated
patients lower than 50% among those for whom OAT
would be appropriate [6-8]. Uncertainty about the bene-
fit/risk balance, fear of major bleeding complications and
poor compliance to coagulation monitoring are the main
factors accounting for under-prescription of OAT by clini-
cians [5].
We recently conducted an audit on the appropriateness of
antithrombotic therapy (AT) at discharge in patients with
NVAF in a large tertiary-care teaching hospital in Turin
(Northern Italy) [6]. From patients at high/very high
stroke risk without OAT contraindications: less than 50%
were properly treated with warfarin, about 30% received
ASA, but more than 20% were discharged without any AT.
As a consequence of these unsatisfactory findings, a
locally-adapted guideline for the prevention of cardioem-
bolic events in patients with NVAF was developed and
implemented in the years 2002–2003.
In the present paper we report the impact of this guideline
on the appropriateness of AT in patients with NVAF,
through a before-and-after controlled study.
Methods
All consecutive patients discharged alive with "chronic
NVAF" coded as a secondary diagnosis (International
Classification of Disease, code 427.31) were identified
from the discharge files of S. Giovanni Battista Hospital of
Turin in the period 1st January–30th June 2000, and 1st Jan-
uary–30th June 2004.
Exclusion criteria were: 1) NVAF as main diagnosis, since
cardioversion and anticoagulation could be employed
according to specific protocols; 2) age >90 years; 3) dis-
charge from surgical units, because of OAT contraindica-
tions (eg recent surgery) or complications (eg NVAF as a
transient arrhythmia after open-heart surgery). Both per-
manent and recurrent NVAF (at least two ECG-docu-
mented episodes either before entry or during
hospitalisation) without potential reversible causes, were
considered, since criteria for anticoagulation are the same
[9].
The clinical records were abstracted by two authors, using
a standardised form. Preliminary random sample of 10%
of the records were independently abstracted by both
authors; areas of disagreement were discussed.
All patients gave their written informed consent to analy-
sis of data from their clinical records, and all procedures
were in accordance with the Declaration of Helsinki.
Risk factors for thromboembolic events were: previous
ischaemic stroke/transient ischaemic attack (TIA)/
embolic event, age ≥ 65 years, hypertension (previous
diagnosis; use of anti-hypertensive drugs), diabetes melli-
tus (chronic elevation of glycaemia; hypoglycaemic med-
ication use), heart failure (history/diagnosis in the
records), documented left ventricular systolic dysfunction
(ejection fraction <40%), coronary artery disease (CAD)
(current/previous chronic angina pectoris; acute coronary
syndrome; coronary re-vascularisation).
The following were considered as OAT contraindications:
pro-haemorrhagic/coagulative disorders, intra-cranial
haemorrhage (history/current), major bleeding within 6-
months (requiring transfusion/hospitalisation), severe
impaired renal function, hepatic cirrhosis, severe psychi-
atric disease, dementia, unreliable patient, severe uncon-
trolled hypertension, history of recurrent falls (≥ 2),
chronic alcoholism, known allergic reaction to warfarin,
previous discontinuation of OAT because of bleeding,
life-expectancy <12 months, difficulty/refusal by the
patient of coagulation monitoring.
A large multidisciplinary panel, composed of 19 physi-
cians from the hospital departments of emergency, inter-
nal medicine, geriatrics, cardiology, neurology,
haematology, epidemiology, and a general practitioner,
worked during 2002–2003 to develop a guideline on AT
for NVAF. The guideline of the Scottish Intercollegiate
Guidelines Network (SIGN) was adapted (see below). A
review of the literature, through electronic databases
(Medline, Cochrane Library), was undertaken to search
papers worth consideration published after the SIGN
guideline and to obtain further data about OAT bleeding
risk. The guideline was adopted in June 2003 [10].
On the basis of the available evidence, OAT resulted asso-
ciated with a greater risk of bleeding in patients ≥ 75 y [1].
A risk stratification model, taking into account the esti-
mated thromboembolic and bleeding risk according to
age below and ≥ 75 years, and the newer risk stratifica-
tions proposed [11], was developed (Table 1). The use of
OAT was considered as either recommended, to be indi-
vidualised, or not recommended. In the absence of con-
traindications, OAT was strongly recommended for
patients of any age at very high risk, and in <75 y patients
at high risk. OAT or ASA were considered appropriate
(and the choice to be individualised) in patients without
contraindications at moderate stroke risk (of any age),
and in high risk ≥ 75 y patients. Since OAT contraindica-
tions include conditions with varying degrees of severity,Page 2 of 8
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contraindication and high-very high thromboembolic
risk, the decision about AT should be based on a careful
individual evaluation of the risk/benefit balance. Lastly,
OAT was considered not recommended in patients at low-
moderate stroke risk and with contraindications.
A before-discharge contact with the general practitioner to
decide the best way of OAT monitoring was suggested;
outpatient monitoring in anticoagulation clinics for eld-
erly or more complicated patients was encouraged.
One of the main task was to identify possible barriers to
the guideline adoption. A major issue was the fear of
bleeding caused by OAT, particularly in the elderly. This
issue was addressed by providing physicians with clear
recommendations, including a weighted balance between
thromboembolic and haemorrhagic risks.
A report of the results of the initial audit hold in 2000,
showing a large under-utilisation of OAT [6] was exten-
sively distributed in the hospital wards. The guideline was
presented to all hospital physicians, sample copies and a
reminder with an easy-to-use coloured table for AT indica-
tions were distributed. Dedicated meetings in each unit
were organised by the multidisciplinary group by schedul-
ing sessions. The guideline was published on a local med-
ical journal, distributed to all the family practitioners, and
ad hoc meetings for them were organised.
The main and the secondary outcomes of the project were,
respectively: an increase in the appropriate OAT prescrip-
tion at discharge, and the increment in patients dis-
charged with any AT. Since only one patient resulted at
low thromboembolic risk, this subject was included in the
moderate risk category.
Based on the results of the first audit, we estimated that a
new sample (at least 300 patients) would be required to
detect with sufficient precision (alpha = 0.05, 2-sided and
beta = 0.20) an absolute increase of at least 15% of OAT
(from 55% to 70%), when strongly recommended (about
1/3 of the total sample).
The absolute difference between proportions was the
main outcome measure; 95% confidence intervals were
calculated using Confidence Interval Analysis, version
2.1.1. A logistic regression analysis was performed to eval-
uate the guideline impact on OAT use at discharge, after
adjustments for age, risk of stroke, OAT contraindications,
AT at admission; the logistic models were also stratified by
period (SAS, version 8.2).
Results
Clinical characteristics of patients with NVAF (n = 313 in
2000; n = 388 in 2004), are presented in Table 2. Com-
pared to patients discharged in 2000, those evaluated in
2004 were slightly older, had higher prevalence of hyper-
tension, heart failure, and lower prevalence of previous
stroke/TIA. The presence of at least one OAT contraindica-
tion was recorded in 106/313 patients (33.9%) in 2000
and in 159/388 patients (41.0%) in 2004.
The distribution of patients according to the guideline rec-
ommendations, by discharge period, is shown in Table 2.
In the second audit, the percentage of patients discharged
with OAT, when strongly recommended, increased signif-
icantly from 56.6% to 81.9% (absolute increase: +25.3%)
(Table 3). When both OAT/ASA were appropriate, the
proportion of patients treated with OAT increased from
40.6% to 54.8%. OAT use increased also in patients with
an uncertain benefit/risk balance (from 12.5% to 29.5%),
but not among patients for whom it was clearly not rec-
Table 1: Guideline risk stratification and recommended antithrombotic therapy.
Classes of thromboembolic 
risk:
Estimated stroke risk (%/
year):
Patients' characteristics and 
risk factors*:
Recommendations†:
Very high risk 12 Previous ischaemic stroke or TIA 
or other embolic event
OAT strongly recommended
High risk, age <75 >5 ≥65 years and at least one risk 
factor
OAT strongly recommended
High risk, age ≥75 >5 ≥65 years and at least one risk 
factor
OAT or ASA recommended
Moderate risk 3–5 <65 years and at least one risk 
factor
or
≥65 years and no risk factors
OAT or ASA recommended
Low risk ≤1 <65 years and no risk factors OAT not recommended
* Risk factors for thromboembolic events include: hypertension, diabetes mellitus, heart failure or left ventricular systolic dysfunction, coronary 
heart disease. †In patients with contraindications to OAT and high or very high risk of stroke the recommended prophylaxis was considered 
uncertain: any decision about the use of OAT, ASA or no prophylaxis should be individualised, balancing the benefits with the risks due to the 
contraindications. OAT, oral anticoagulant therapy; ASA, acetylsalicylic acid.Page 3 of 8
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discharged with any AT (OAT/ASA), when recommended,
increased from 158/207 (76.3% in 2000) to 204/229
(89.1% in 2004), with an absolute increase of +12.8%
(95%CI:6.8% 18.7%).
The use of OAT at admission, among patients for whom
OAT was strongly recommended, increased from 36.8%
to 58.1% (+21.3%), while the prevalence of patients
either treated with ASA or receiving no AT drugs declined
(from respectively 29.2% to 23.8%, and 34.0% to 18.1%
-data not shown-). Overall, the percentage of patients
without OAT contraindications admitted with AT (OAT or
ASA) increased from 58.4% in 2000 to 74.7% in 2004 (p
< 0.001).
The OAT prescription at discharge was analysed by a logis-
tic regression model, including the following variables:
study-period, stroke risk, OAT contraindications, age, AT
at admission (Table 4). The adjusted OR for OAT prescrip-
tion was 2.11 (95%CI:1.47 3.04) for the study period
(2004 vs 2000). Age >75 and presence of contraindica-
tions were both strong negative predictors of OAT, with-
out variation between periods. Meanwhile, OAT
prescription was positively associated with the patient's
stroke risk only in the 2004 sample. AT at admission was
a much stronger predictor of OAT therapy at discharge in
2000 than in 2004.
Discussion
The implementation of guidelines for AT in NVAF patients
may be an effective tool for improving appropriateness of
OAT prescription at discharge. An absolute 25% increase
in the appropriate prescription of OAT at discharge was
observed. Remarkably, very few patients were discharged
without any AT in 2004 as compared with 2000. An abso-
lute 14% increase in OAT use in 2004 as compared with
2000 was also observed among patients for whom the
decision on best AT should be individualised.
Epidemiological surveys indicated that there is a temporal
trend in the use of OAT: the proportion of patients with
NVAF treated with warfarin ranged from 20% to 53% in
the early 90s [12,13], rose to 48–55% in the years 1995–
1997 [14,15], and up to 50–58% around the year 2000
[16,17]. It appears that most of the increasing trend in
Table 2: Clinical characteristics and distribution of patients according to the recommended treatment, by period of discharge.
Clinical characteristics 2000 2004
N (%) N (%)
Patients 313 (100.0) 388 (100.0)
Males 159 (50.8) 193 (49.7)
< 70 years 65 (20.8) 71 (18.3)
70–79 years 135 (43.1) 163 (42.0)
≥ 80 years 113 (36.1) 154 (39.7)
Hypertension 232 (74.1) 326 (84.0)
Previous stroke/TIA 100 (31.9) 95 (24.5)
Diabetes mellitus 77 (24.6) 91 (23.4)
Heart failure 146 (46.6) 209 (53.9)
Coronary heart disease 96 (30.7) 114 (29.4)
Recommended treatment: N (%) N (%)
OAT strongly recommended*: 106 (33.9) 105 (27.1)
▪ Very high risk of stroke 62 (19.9) 45 (11.6)
▪ High risk of stroke, age < 75 44 (14.0) 60 (15.5)
OAT or ASA recommended†: 101 (32.3) 124 (32.0)
▪ High risk of stroke, age ≥ 75 67 (21.4) 94 (24.2)
▪ Moderate risk of stroke 34 (10.9) 30 (7.7)
Uncertain‡ 96 (30.7) 146 (37.6)
▪ Very high risk of stroke 58 (18.5) 96 (24.7)
▪ High risk of stroke 38 (12.1) 50 (12.9)
OAT not recommended§ 10 (3.2) 13 (3.3)
*Patients without contraindications to OAT and a favourable balance for AT, for whom OAT is the preferred choice. †Patients without 
contraindications to OAT and a favourable balance for AT, but the choice between OAT or ASA should be individualised. ‡Patients with 
contraindications to OAT and high or very high risk of stroke: any decision about the use of OAT, ASA or no AT should be individualised, balancing 
the benefits with the risks due to the contraindications. §Patients with contraindications to OAT and low-moderate risk of stroke. OAT, oral 
anticoagulant therapy; AT, antithrombotic therapy; ASA, acetylsalicylic acid.Page 4 of 8
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years after the publication of the clinical trials between
1989–1992 [14], while in more recent years OAT seems to
have reached a plateau [8].
Few studies aimed at improving appropriateness of AT
prophylaxis in patients with NVAF have been reported.
The combination of physician/nurse education and use of
an OAT monitoring service have led to substantial
improvements both in the percentage of properly treated
patients (88%), and in the incidence of effective anticoag-
ulation among the ambulatory patients [18]. The use of a
patient decision aid on AT in NVAF was associated with a
12% absolute improvement in the number of patients
receiving appropriate therapy, even if this beneficial effect
did not persist [19]. Programs of guideline implementa-
tion for general practitioners, or within hospitals, deter-
mined a significant increase in warfarin use in high risk
patients, even though the prevalence of properly treated
patients was still sub-optimal, ranging from 46% to 73%
[20,21]. A multifaceted intervention involving nine Aus-
tralian teaching hospitals resulted in a higher rate of AT
prescription (92%), although the authors did not stratify
patients according to their thromboembolic risk, but con-
sidered appropriate AT use in the absence of contraindica-
tions [22]. A pharmacist-led-multidisciplinary
intervention in older in-patients increased AT use (from
60% to 81%), even if about a fifth of patients were still
discharged without any prophylaxis [23].
Previous studies demonstrated that in clinical practice
OAT prescription is often in weak accordance with the
individual patients' risk of stroke, and that the non-use of
warfarin is not always motivated by the presence of OAT
contraindications.
Several clinician-related concerns (including the fear of
bleeding complications, the perceived poor compliance of
patients to long-term therapy) and poor risk perception
together with misunderstanding of the true risk/benefit
balance of OAT by patients themselves, might account for
OAT under-use even in patients without contraindications
to its use [24,25]. Therefore, some studies documented a
poor OAT use rather than an under-use: older patients at
high risk were often not given warfarin in favour of
younger, low-risk AF patients [26]. In order to overcome
these potential drawbacks when deciding AT, we devel-
oped guidelines including a list of contraindications to
OAT and recommendations for AT expressed as age/spe-
cific risk/benefit balance. Overall, the proportion of
patients with no contraindications who were discharged
with OAT doubled in 2004 as compared with 2000.
Remarkably, an increase of OAT use was observed only in
high or very high risk patients (+17%), for whom the
appropriate balance between risks and benefits is uncer-
tain, while it was reduced in moderate risk patients (-
12%), where OAT was clearly not recommended.
Even if implementing guidelines may also drive some
potential side effects, as previously observed in our hospi-
tal, where the higher rates of appropriate procedure use
were associated with higher rate of inappropriate use [27],
the present findings clearly indicate that the guideline
implementation improved the appropriateness of OAT
prescription, rather than simply extending its use. Indeed,
warfarin use at discharge was strongly associated with the
individual stroke risk level only in 2004, while its use was
negatively associated with older age and presence of con-
traindications in both study periods. Thus, a general pos-
itive impact of the guideline on improvement of the
clinical practice by a better evaluation of the individual
benefit-to-risk ratio has been achieved by a tailored imple-
mentation strategy of a locally adapted guideline.
More efficient ways to transfer important evidence-based
knowledge into usual clinical practice are needed, in order
to further reduce the proportion of patients discharged
without any prophylaxis (e.g. feedback to physicians,
alternative care delivery programs, including increased
patient participation) [28].
Table 3: Patients discharged with OAT or with any treatment (OAT/ASA), by the recommended treatment, before-and-after 
implementation.
2000 (N = 313) 2004 (N = 388) Absolute difference (2004–2000) in 
the prevalence of patients discharged 
with:
Recommended treatment*: Total OAT OAT or ASA Total OAT OAT or ASA OAT OAT or ASA
N N (%) N (%) N N (%) N (%) % (95%CI) % (95%CI)
OAT strongly recommended 106 60 (56.6) 91 (84.8) 105 86 (81.9) 101 (96.2) +25.3 (14.9 34.9) +10.3 (3.9 17.2)
OAT or ASA recommended 101 41 (40.6) 67 (66.3) 124 68 (54.8) 103 (83.1) +14.2 (3.2 24.8) +16.7 (7.2 26.2)
Uncertain 96 12 (12.5) 50 (52.1) 146 43 (29.5) 112 (76.7) +17.0 (8.1 24.9) +24.6 (14.3 34.5)
OAT not recommended 10 2 (20.0) 5 (50.0) 13 1 (7.7) 8 (61.5) -12.3 (-39.0 12.2) +11.5 (-20.6 41.1)
*See footnote to table 2Page 5 of 8
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although our data may reflect a local reality, the propor-
tion of properly treated patients is not discordant from
previous reports in other countries [20,23].
As in all chart-review based-studies, there is a potential for
misclassification bias. Although data were carefully
abstracted and jointly evaluated, we cannot exclude that
some important information regarding the anticoagula-
tion decision and/or existing contraindications to warfa-
rin, might have been missed.
A common limitation of the before/after design in evalu-
ating the health intervention effectiveness is the possibil-
ity that the changes observed are merely expression of a
temporal trend. This trend is well documented by the
increased proportion of patients on OAT at admission.
However, this should not be the case of our findings,
because multivariate analysis showed that OAT appropri-
ateness at discharge was improved, as a consequence of
the project, also after taking into account AT at admission.
The CHADS2 score, a recently proposed and validated
stroke risk index, allows an easy and practical risk stratifi-
cation [29]. However, at the time the hospital guideline
was planned, it was validated in a single study on a large
not-European cohort. Only recently, in fact, the predictive
role of this score has been validated in an Italian cohort
[30].
The classification of the American College of Chest Physi-
cian (ACCP) represents another scheme for cardioem-
bolic risk stratification [31]. Our scheme differs from the
ACCP classification with regard to the following points: i)
a higher weight was attributed to prior stroke/TIA, which
by itself determined a very high risk, in line with CHADS2
criteria; ii) other risk factors were given the same weight;
iii) the hemorrhagic risk of treatment was combined with
its antithrombotic effect, and age ≥ 75 years was consid-
ered as a cut-off associated with a greater bleeding risk
with OAT use [1].
Recently, the American College of Cardiology, the Ameri-
can Heart Association, and the European Society of Cardi-
ology proposed a joint stratification which recognised a
higher risk to previous stroke/TIA or embolism, and gave
the same weight to diabetes, hypertension, heart failure/
left ventricular dysfunction, which were moderate risk fac-
tors [32].
All these schemes did not consider the bleeding risk, when
recommending the treatment of choice.
Conclusion
Our intervention, which involved a large group of end-
users in implementing a hospital guideline, has improved
the clinical practice through a better evaluation at the
patient's individual level of the benefit to risk ratio in
deciding the appropriate AT.
Table 4: Predictors of OAT prescription at discharge in the whole sample, before, and after the guideline.
Whole sample Period:
2000 2004
OR* (95% CI) OR* (95% CI) OR* (95% CI)
Risk of stroke:
▪ Moderate 1 - 1 - 1 -
▪ High 0.99 (0.55 – 1.76) 0.45 (0.19 – 1.03) 2.18 (0.96 – 4.94)
▪ Very high 1.48 (0.78 – 2.80) 0.58 (0.23 – 1.44) 3.92 (1.55 – 9.93)
Contraindications to OAT:
▪ None 1 - 1 - 1 -
▪ One or more 0.18 (0.13 – 0.27) 0.17 (0.09 – 0.34) 0.19 (0.11 – 0.30)
Age:
▪ < 75 1 - 1 - 1 -
▪ ≥ 75 0.30 (0.21 – 0.45) 0.35 (0.19 – 0.62) 0.26 (0.15 – 0.43)
AT at admission:
▪ No 1 - 1 - 1 -
▪ Yes 3.03 (2.08 – 4.43) 4.88 (2.74 – 8.69) 2.07 (1.23 – 3.47)
Period:
▪ 2000 1 - - - - -
▪ 2004 2.11 (1.47 – 3.04) - - - -
(*)Odds ratios (OR) and 95% confidence intervals (95% CI) adjusted for all the variables listed in the table with logistic regression models.
OAT, oral anticoagulant therapy; AT, antithrombotic therapy.Page 6 of 8
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improved clinical practice might be maintained in the
long-term, and whether it may translate into improved
outcomes.
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